A machine hailed as a “Precision Surgery Expert” has been introduced AI Intelligent Microwave Ablation Robot at the People’s Hospital of Zheng’an County bringing good news to patients in the county and surrounding areas Recently, the lung cancer screening project supported by the Hengqin Guangdong-Macao Deep Cooperation Zone was officially launched, and the advanced navigation … Read more
A machine known as the “Precision Surgery Expert” has been introduced AI Intelligent Microwave Ablation Robot has been established at the Zheng’an County People’s Hospital bringing good news to patients in the county and surrounding areas Recently, the lung cancer screening project supported by the Hengqin Guangdong-Macao Deep Cooperation Zone has officially launched, with the … Read more
WCLC 2025 has numerous topics on ADCs, and in the spirit of learning, I am joining the discussion. Let’s see how ADCs are viewed in the field of lung cancer, a leading area in cancer treatment, and what research directions exist for ADCs in this domain.Biomarkers for ADCs: IHC and Beyond, presented by Dr. Sewanti … Read more
Compiled by: Oncology NewsSource: Oncology News In the field of lung cancer treatment, patients with EGFR-mutated non-small cell lung cancer (NSCLC) have long faced a “treatment desert” after developing resistance to TKI therapy, with traditional chemotherapy offering limited efficacy and significant side effects. The Chinese innovative drug, sacituzumab tirapazamine, developed by Professor Zhang Li’s team, … Read more
Follow below to not miss cancer knowledge~ 1 Three Major Therapies for Lung Cancer Have Shortcomings, Urgent Need for Innovative Drugs In recent years, significant progress has been made in the treatment of advanced non-small cell lung cancer, with a growing variety of therapeutic drugs leading to a triad of targeted, immunotherapy, and chemotherapy. Targeted … Read more
Abstract National Natural Science Foundation Project Report HER2 exon 20 insertion mutations (HER2 20ins) are the most common type of HER2 mutations in lung cancer, accounting for 62%-90%. However, the response rate of these patients to existing targeted drugs (such as TKIs) is only 10%-30%, and the mechanisms of resistance have long been unclear. The … Read more
01 In the treatment of non-small cell lung cancer (NSCLC), a subtype characterized by the deletion of the LKB1 gene has long left clinicians at a loss. These tumors are referred to as “immune deserts”—with almost no trace of anti-cancer T cells, they exhibit near-complete resistance to PD-1/PD-L1 immune checkpoint inhibitors (ICIs), resulting in poor … Read more
In 2019, a CT imaging comparison from Gustave Roussy Hospital in Paris, France, caused a stir in the oncology community: a late-stage non-small cell lung cancer patient, who had failed both chemotherapy and immunotherapy, showed significant reduction in systemic metastatic lesions just two months after being enrolled in the clinical trial of Trastuzumab Deruxtecan (T-DXd), … Read more
Click below to follow and learn more about anti-cancer knowledge 👇 For patients with HER2 mutations in non-small cell lung cancer, past treatments have primarily involved chemotherapy, immunotherapy combined with chemotherapy, and anti-angiogenic therapy combined with chemotherapy. With the rise of antibody-drug conjugates (ADC), the treatment prospects for HER2 mutation patients are becoming increasingly clear. … Read more
Last week, while introducing the “Breakthroughs and Innovations in Lung Cancer Treatment” from the “AACR 2021 Annual Report on Anti-Cancer Progress”（>> Click to review）, I mentioned a popular research topic—Antibody-Drug Conjugates (ADCs), which saw two new ADCs approved and two ADCs expanding their indications in 2021. Some readers expressed a desire to learn more about … Read more